Open AccessApplicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice
Author(s) -
Muthiah Vaduganathan,
Stephen J. Greene,
Shuaiqi Zhang,
Maria V. GrauSepulveda,
Adam D. DeVore,
Javed Butler,
Paul A. Heidenreich,
Joanna Huang,
M. Kittleson,
Karen E. Joynt Maddox,
James McDermott,
Anjali Owens,
Pamela N. Peterson,
Scott D. Solomon,
Orly Vardeny,
Clyde W. Yancy,
Gregg C. Fonarow
Publication year - 2020
Publication title -
jama cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.108
H-Index - 63
eISSN - 2380-6591
pISSN - 2380-6583
DOI - 10.1001/jamacardio.2020.5864
Subject(s) - dapagliflozin , medicine , ejection fraction , heart failure , food and drug administration , generalizability theory , drug , clinical trial , adverse effect , intensive care medicine , cardiology , pharmacology , diabetes mellitus , endocrinology , type 2 diabetes , statistics , mathematics
In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. Limited data are available characterizing the generalizability of dapagliflozin to US clinical practice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom